Stomach cancer remains one of the deadliest malignancies worldwide, partly because conventional treatments fail to eradicate the small subpopulation of cells responsible for tumor initiation, recurrence, and therapy resistance. A discovery pinpointing a specific molecular marker on gastric cancer stem cells could reframe how oncologists approach this notoriously difficult disease — shifting focus from bulk tumor reduction to eliminating the cells at the root of the problem.
Researchers at A*STAR in Singapore identified a distinct surface marker that reliably distinguishes gastric cancer stem cells from surrounding tumor cells. Using this marker, they were able to isolate and characterize this subpopulation, then demonstrate in experimental models that selectively targeting cells bearing this marker significantly disrupted tumor growth. The findings suggest that depleting this stem-cell reservoir — rather than attacking the broader tumor mass — may improve treatment outcomes, particularly in cases where conventional chemotherapy has failed or led to relapse.
This work fits into a decade-long shift in oncology toward cancer stem cell (CSC) theory, which holds that a hierarchical minority of self-renewing cells drives tumor maintenance and metastasis. While CSC markers have been proposed for colorectal, breast, and liver cancers, gastric cancer has lagged behind in validated targets — making this identification potentially clinically meaningful. The key limitation here is that the current evidence appears to derive from preclinical models; translation to human clinical trials remains the critical, unproven step. CSC markers also carry a risk of heterogeneity — the same marker may not be uniformly expressed across all gastric cancer subtypes or patient populations. Still, for a cancer with a five-year survival rate that remains below 30% globally, a credible new molecular target is an incremental but genuinely useful advance worth monitoring as trial-phase data emerge.